SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses Significant Stake in Hologic Inc.
Beneficial Ownership Report
T. Rowe Price Investment Management, Inc. has filed an updated Schedule 13G, revealing a 7.9% beneficial ownership stake in Hologic Inc.'s common stock as of December 31, 2024.
Summary
- T. Rowe Price Investment Management, Inc. has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Hologic Inc.
- As of December 31, 2024, T. Rowe Price Investment Management, Inc. beneficially owns an aggregate of 17,938,833 shares of Hologic Inc. common stock.
- This ownership represents 7.9% of the class of Hologic Inc.'s common stock.
- The firm holds sole voting power over 17,897,429 shares and sole dispositive power over 17,938,833 shares.
- T. Rowe Price Investment Management, Inc. is classified as an Investment Adviser (IA) and is based in Maryland.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. While neutral in tone, the disclosure of a significant stake by a major institutional investor like T. Rowe Price can be perceived as a positive signal of confidence in the issuer, Hologic Inc.
Positives
- The disclosure of a significant 7.9% stake by a reputable investment adviser like T. Rowe Price Investment Management, Inc. may signal institutional confidence in Hologic Inc.
Negatives
- This Schedule 13G filing does not contain information typically categorized as 'negatives' regarding the issuer's performance or outlook.
Risks
- This Schedule 13G filing does not contain information regarding specific risks related to Hologic Inc.'s operations or financial performance.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Hologic Inc.'s future outlook.
Management Comments
- T. Rowe Price Investment Management, Inc. certified that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Hologic Inc.
- The filing also states that T. Rowe Price Investment Management, Inc. expressly denies beneficial ownership of the securities, clarifying that the filing of Schedule 13G should not be construed as an admission of such ownership.
Industry Context
This filing reflects a specific institutional investment position and does not provide broader analysis of industry trends or competitive landscape for Hologic Inc.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by T. Rowe Price Investment Management, Inc. may be viewed positively by existing and potential shareholders, potentially indicating confidence in Hologic Inc.'s long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement, indicating the beneficial ownership position as of this date. |
| 02/14/2025 | Date the Schedule 13G Amendment No. 2 was signed by T. Rowe Price Investment Management, Inc. |
Keywords
Hologic Inc, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.